SCHLIEREN / ZURICH, Switzerland–(BUSINESS WIRE)–Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the closing of a CHF25 …
Read Full Story at source (may require registration)
Latest posts by CHF Editor (see all)
- Technical talk: EUR/CHF rejecting monthly resistance - January 24, 2024
- USD/CHF moves higher to near 0.8680 as Fed members maintain a hawkish stance - January 24, 2024
- Holcim price target lowered by CHF 2 at Barclays - January 24, 2024